Filtered By:
Infectious Disease: Influenza

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 693 results found since Jan 2013.

OASL1-Mediated Inhibition of Type I IFN Reduces Influenza A Infection-Induced Airway Inflammation by Regulating ILC2s
CONCLUSIONS: OASL1 may impede the IAV-induced acute airway inflammation that drives AHR by inhibiting IAV-induced type I IFN production from lung DCs, thereby preserving the functions of lung ILC2s, including their amphiregulin production.PMID:34983110 | PMC:PMC8724833 | DOI:10.4168/aair.2022.14.1.99
Source: Allergy, Asthma and Immunology Research - January 4, 2022 Category: Allergy & Immunology Authors: Yuna Chang Ji-Seon Kang Keehoon Jung Doo Hyun Chung Sang-Jun Ha Young-Joon Kim Hye Young Kim Source Type: research

Researchers to Study Why COVID-19 Strikes Asthma Sufferers Less Severely Than Others
A University of Arizona Health Sciences-led research team received $7.16 million in federal funding to study how to better control severe asthma and determine why sufferers are less likely to contract COVID-19, influenza and rhinovirus. Today University of Arizona Health Scienceswomen_blowing_nose-948301830-hero-web.jpgHealthCollege of Medicine - TucsonExpertsExplorationResearchAn investigation into why asthma sufferers are less likely to contract COVID-19 is one of several aims for research funded through a $7.16 million National Institutes of Health cooperative agreement with the  Asthma and Airway Disease Research ...
Source: The University of Arizona: Health - December 9, 2021 Category: Universities & Medical Training Authors: mittank Source Type: research

A083 maximizing influenza vaccine rates in allergy shot patients
Immunizations are a fundamental part of healthcare. Immunization status should be screened at each clinic visit. Subcutaneous immunotherapy (SCIT) and biologic patients visit allergy clinics regularly for injections and provide frequent opportunities to assess immunization status, specifically the annual influenza vaccine. Studies reveal patients are more likely to receive vaccinations when recommended by a medical provider. Annual influenza vaccine rates were 48.4% during the 2019-20 influenza season in the  US.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: J. Gubin, M. Tankersley Source Type: research

Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe ...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase 2b CYPR...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine: a rapid scoping review
Conclusions Due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.
Source: BMJ Open - September 17, 2021 Category: General Medicine Authors: Lunny, C., Antony, J., Rios, P., Williams, C., Ramkissoon, N., Straus, S. E., Tricco, A. C. Tags: Open access, Immunology (including allergy), COVID-19 Source Type: research

Interleukin-5 Receptor alpha (CD125) Expression on Human Blood and Lung Neutrophils
CONCLUSION: In addition to expression on eosinophils and basophils, the IL-5Rα is consistently and abundantly expressed on the surface of blood and especially airspace neutrophils. These observations support the concept that some of the efficacy of IL5/IL-5R-targeting biologics observed in asthma may reflect their ability to target neutrophilic airspace inflammation.PMID:34391897 | DOI:10.1016/j.anai.2021.08.004
Source: Annals of Allergy, Asthma and Immunology - August 15, 2021 Category: Allergy & Immunology Authors: Monica G Lawrence W Gerald Teague Xin Feng Caitlin Welch Elaine Etter Julie Negri Marthajoy Spano Kristin Wavell Thomas Braciale John W Steinke Larry Borish Source Type: research

Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases
Vaccine. 2021 Aug 5:S0264-410X(21)00964-6. doi: 10.1016/j.vaccine.2021.07.071. Online ahead of print.ABSTRACTModern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institut...
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: M Patricia D'Souza Amy C Palin Thomas Calder Hana Golding Steven H Kleinstein Erin L Milliken David O'Connor Georgia Tomaras Jon Warren Cesar Boggiano Source Type: research